Amneal Pharmaceuticals, Inc. Class A Common Stock Net Assets
Amneal Pharmaceuticals, Inc. Class A Common Stock net assets. Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has net assets worth $640.71 Million USD as of September 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.27 Billion) and total liabilities ($4.63 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Amneal Pharmaceuticals, Inc. Class A Com net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $640.71 Million |
| % of Total Assets | 12.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | -98.38% |
| 10-Year Change | N/A |
| Growth Volatility | 59.08 |
Net Assets of Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
Net assets of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2025. This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's net assets have evolved over time, based on quarterly financial data. See AMRX equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
The table below shows the annual net assets of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2025. For live market cap and overall valuation, see Amneal Pharmaceuticals, Inc. Class A Com (AMRX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.96 Million | +113.39% |
| 2024-12-31 | $-44.54 Million | -172.65% |
| 2023-12-31 | $61.30 Million | -70.66% |
| 2022-12-31 | $208.93 Million | -43.07% |
| 2021-12-31 | $366.97 Million | +2.87% |
| 2020-12-31 | $356.74 Million | +2.87% |
| 2019-12-31 | $346.79 Million | -61.31% |
| 2018-12-31 | $896.36 Million | +338.66% |
| 2017-12-31 | $-375.58 Million | -113.47% |
| 2016-12-31 | $-175.94 Million | +5.85% |
| 2015-12-31 | $-186.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amneal Pharmaceuticals, Inc. Class A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35303100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Amneal Pharmaceuticals, Inc. Class A Common Stock Net Assets Breakdown (December 2025)
Amneal Pharmaceuticals, Inc. Class A Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.15 Million | % |
| Other Comprehensive Income | $-110.73 Million | % |
| Other Components | $571.79 Million | % |
| Total Equity | $-70.79 Million | 100.00% |
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Market Cap
The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CarMax Inc
NYSE:KMX
|
$7.46 Billion |
|
WT Microelectronics Co Ltd
TW:3036
|
$7.47 Billion |
|
Timken Company
NYSE:TKR
|
$7.48 Billion |
|
Tongwei Co Ltd
SHG:600438
|
$7.48 Billion |
|
AURUBIS AG UNSP.ADR 1/2
F:NDA1
|
$7.45 Billion |
|
Eastman Chemical Company
NYSE:EMN
|
$7.44 Billion |
|
InterDigital Inc
NASDAQ:IDCC
|
$7.43 Billion |
|
Hongfa Technology Co Ltd
SHG:600885
|
$7.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amneal Pharmaceuticals, Inc. Class A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -109,267,000 to -70,794,000, a change of 38,473,000.
- Net income of 72,057,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 45,219,001.
- Other factors increased equity by 11,635,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $72.06 Million | +101.78% |
| Other Comprehensive Income | $-45.22 Million | -63.87% |
| Other Changes | $11.64 Million | +16.44% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Amneal Pharmaceuticals, Inc. Class A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-1.03 | $21.38 | x |
| 2016-12-31 | $-0.98 | $21.38 | x |
| 2017-12-31 | $-3.36 | $21.38 | x |
| 2018-12-31 | $7.04 | $21.38 | x |
| 2019-12-31 | $1.76 | $21.38 | x |
| 2020-12-31 | $2.04 | $21.38 | x |
| 2021-12-31 | $2.37 | $21.38 | x |
| 2022-12-31 | $1.98 | $21.38 | x |
| 2023-12-31 | $0.11 | $21.38 | x |
| 2024-12-31 | $-0.35 | $21.38 | x |
| 2025-12-31 | $-0.22 | $21.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amneal Pharmaceuticals, Inc. Class A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.39%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-55.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 19.56% | 0.85x | 0.00x | $188.97 Million |
| 2016 | 0.00% | 20.37% | 0.84x | 0.00x | $225.91 Million |
| 2017 | 0.00% | 16.22% | 0.77x | 0.00x | $206.22 Million |
| 2018 | -18.93% | -10.21% | 0.38x | 4.86x | $-259.36 Million |
| 2019 | -155.99% | -22.25% | 0.44x | 15.80x | $-385.12 Million |
| 2020 | 30.03% | 4.57% | 0.50x | 13.21x | $60.73 Million |
| 2021 | 2.95% | 0.51% | 0.53x | 10.93x | $-25.41 Million |
| 2022 | -43.56% | -5.88% | 0.58x | 12.73x | $-159.83 Million |
| 2023 | -424.61% | -3.51% | 0.69x | 175.55x | $-85.97 Million |
| 2024 | 0.00% | -4.18% | 0.80x | 0.00x | $-105.96 Million |
| 2025 | 0.00% | 2.39% | 0.82x | 0.00x | $79.14 Million |
Industry Comparison
This section compares Amneal Pharmaceuticals, Inc. Class A Common Stock's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $142,968,828
- Average return on equity (ROE) among peers: -68.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $640.71 Million | 0.00% | 7.22x | $7.45 Billion |
| Aurora Cannabis Inc (ACB) | $690.35K | -57.00% | 0.04x | $324.78 Million |
| ADC Therapeutics SA (ADCT) | $140.89 Million | 0.00% | 0.10x | $188.49 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.94 Million |
| Akebia Ther (AKBA) | $131.00 Million | -46.35% | 0.09x | $127.03 Million |
| Alkermes Plc (ALKS) | $21.20 Million | -64.84% | 0.73x | $7.89 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $305.26 Million | -47.41% | 0.09x | $3.89 Billion |
| Amphastar P (AMPH) | $448.72 Million | 0.31% | 0.41x | $1.25 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $222.77 Million | 14.61% | 0.08x | $179.50 Million |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms … Read more